Latest Content

New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here's what psychiatrists and mental health clinicians should know in the era of legalization.

HHS rolls out a plan to curb psychiatric overprescribing, pushing deprescribing guidance as APA and AFSP urge caution and access to care.

New analysis ranks lumateperone top for adjunctive MDD symptom relief, with minimal weight gain vs other atypical antipsychotics.

Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.

Round on the latest news in psychiatry from the last week.

Learn when CBT/IPT beats medications, when to combine antidepressants, and why patient preference drives depression recovery in 6–12 weeks in this podcast.

New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.

In the wake of the FDA fast-track of psychedelic therapies, we want to hear your clinical pearls for our May theme.

A psychiatrist and psychiatric nurse practitioner discuss collaboration and patient support.

The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.

Clinicians explore neuroscience-guided off-label prescribing.

DSM-6 forces psychiatry to choose: sharper science or softer labels. Explore why validity, biomarkers, and hierarchy matter for credibility.

The triple-blinded EPISODE trial with active placebo and 4 dosing regimens yielded mixed results, reflecting the challenge of discerning psilocybin effect and distinguishing between enlightenment and expectation.